Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study

IRRs with amivantamab were predominantly low grade and limited to first infusion, and rarely occurred with subsequent dosing. Close monitoring for IRR with the initial amivantamab dose and early intervention at first IRR signs/symptoms should be part of routine amivantamab administration.